Abstract
In recent years, an increased interest in the efficacy of intrauterine infusion of autologous platelet-rich plasma (PRP) in women with repeated implantation failure (RIF) has resulted in the publication of 13 randomized controlled trials (RCTs) and 11 meta-analyses. Although these meta-analyses support an increase in pregnancy rates after intrauterine infusion of autologous PRP, the low quality of the available original clinical studies along with concerns regarding their trustworthiness seriously questions their internal validity and does not allow for definitive conclusions to be drawn. In addition, the variability in the definition of RIF used in the individual studies limits their external validity, renders the pooling of the results problematic, and, overall, complicates the extrapolation of the results published. The variability in the definition of RIF has been recently addressed by the ESHRE, which published an evidence-based definition of RIF to facilitate the evaluation of interventions in these patients. Taking into consideration this definition, which identifies a real clinical problem, evaluation of intrauterine infusion of PRP in the published literature has not so far been performed explicitly in patients with RIF. The potential of intrauterine infusion of autologous PRP to improve outcomes for women with RIF remains an important area of research in ART. However, the current evidence is insufficient to inform clinical practice, highlighting the need for well-designed studies to provide clearer guidance.